



Mesa Verde Venture Partners of San Diego lead \$700,000 Series A financing for Satiogen Pharmaceuticals

San Diego – Satiogen Pharmaceuticals has recently raised a \$700,000 Series A financing led by Mesa Verde Venture Partners of San Diego. Also participating in the financing was Ted Greene.

Satiogen Pharmaceuticals is a startup biotech company co-founded by Andrew Young, M.D., Ph.D.

Satiogen is working toward human proof of a novel therapeutic principle for inducing weight loss. The Company plans to enter into human testing during 2008.

Daniel C. Wood, CFA, founding General Partner of Mesa Verde Venture Partners and co-founding General Partner of IngleWood Ventures, is Acting CEO of Satiogen Pharmaceuticals.

Dr. Young is an internationally respected physiologist in the field of metabolic diseases. He joined Amylin Pharmaceuticals, Inc in 1989 where he played key rolls in the pre-clinical development of the antidiabetic drugs, BYETTA and SYMLIN.

Ted Greene was founding CEO of Hybritech in 1979, generally credited with launching the biotech industry in San Diego and of Amylin Pharmaceuticals in 1987, and has participated in the founding or management of 10 other medical

technology companies.

Mesa Verde, started in 2006, has a charter to invest in seed venture capital rounds of biomedical companies in Southern California, Utah, New Mexico and Arizona. Mesa Verde's lead investor is Sanderling Ventures, a Top Ten U.S. Biomedical Venture Capital Fund.

Dan Wood states, "I am tremendously gratified to see world-class scientific talent and board level expertise come together to seek proof-of-principle of a novel drug concept for addressing a large and growing healthcare problem."

Dr. Young, Mr. Greene (Chairman) and Mr. Wood serve on Satiogen Pharmaceuticals' Board of Directors.

If the proof-of-principle study demonstrates a relevant therapeutic effect, the Company will seek a larger Series B financing and a full-time CEO.

Contact: Daniel C. Wood
858/245-5045
danwood@ix.netcom.com

